Research progress of peritoneal metastasis from gastric cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

LI Dongdong , HU Chunhua , XIANG Honggang ,  CHEN Lei

Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200092, P. R. China;

Corresponding author：

CHEN Lei, Email: fcyc6110@126.com

Keywords：

gastric cancer; peritoneal metastasis; pathogenesis; diagnosis; therapy

DOI：

10.7507/1007-9424.201703089

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To understand research progress on peritoneal metastasis from gastric cancer at present stage briefly. Methods The literatures about mechanism, diagnosis, prevention and treatment of the peritoneal metastasis from gastric cancer at home and aboard were collected to make a review. Results The peritoneal metastasis is the common site of the distant metastasis in the advanced gastric cancer. It’s occurrence mechanism is complex, the diagnostic measure is varied, the prevention way is difficulty, and it give priority to with the comprehensive treatment and the transformed therapy. Conclusion It has a certain necessity to study occurrence mechanism, prevention methods and treatment measures so that improve survival rate and prognosis for patients with peritoneal metastasis from advanced gastric cancer.

Citation： LI Dongdong, HU Chunhua, XIANG Honggang, CHEN Lei. Research progress of peritoneal metastasis from gastric cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2017, 24(12): 1532-1535. doi: 10.7507/1007-9424.201703089 Copy

1.	Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin, 2017, 67(1): 7-30.
2.	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
3.	Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends-An update. Cancer Epidemiol Biomarkers Prev, 2016, 25(1): 16-27.
4.	梁寒. 腹腔热灌注化疗技术临床应用专家共识(2016 版)解读—胃癌腹膜转移的防治.临床外科杂志, 2017, 25(1): 20-23.
5.	宾业鸿, 胡晓桦. 胃癌腹膜转移发病机制及治疗的研究进展. 广西医学, 2016, 38(10): 1422-1426.
6.	Yamamoto M, Baba H, Kakeji Y, et al. Prognostic significance of tumor markers in peritoneal lavage in advanced gastric cancer. Oncology, 2004, 67(1): 19-26.
7.	朱正纲. 充分重视胃癌腹膜转移的预防、诊断与治疗. 外科理论与实践, 2003, 8(1): 16-17.
8.	戴冬秋. 胃癌腹膜转移研究之策略. 世界华人消化杂志, 2005, 13(9): 1049-1051.
9.	何涛, 杨志明, 伍晓汀. 胃癌腹膜播散转移机理的研究进展. 中国普外基础与临床杂志, 2005, 12(1): 43-45.
10.	赵宏伟, 刘宏斌, 李文惠. 胃癌腹膜转移机理研究现状. 现代肿瘤医学, 2009, 17(5): 978-981.
11.	Sodek KL, Murphy KJ, Brown TJ, et al. Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis. Cancer Metastasis Rev, 2012, 31(1-2): 397-414.
12.	王松岩, 任克, 刘伟. 胃癌腹膜转移的 CT 诊断价值与影像分析(附45例分析). 中国临床医学影像杂志, 2002, 13(4): 296-297.
13.	刘移忠. 胃癌腹膜转移的螺旋 CT 诊断. 中国当代医药, 2011, 18(17): 63, 66.
14.	严超, 朱正纲, 燕敏, 等. 多排 CT 对胃癌腹膜转移术前预测的单中心大宗病例研究. 中华胃肠外科杂志, 2010, 13(2): 106-110.
15.	杨秋蒙, 坂东悦郎, 川村泰一, 等. PET-CT 诊断胃癌腹膜转移的临床价值. 上海交通大学学报(医学版), 2007, 27(5): 573-576.
16.	周江枫, 岳建国, 贺锋, 等. MSCT 及 PET-CT 对胃癌腹膜转移的诊断价值探讨. 山东医药, 2013, 53(6): 59-60.
17.	De Andrade JP, Mezhir JJ. The critical role of peritoneal cytology in the staging of gastric cancer: an evidence-based review. J Surg Oncol, 2014, 110(3): 291-297.
18.	张贤坤, 朱万坤, 韩晓鹏, 等. 胃癌腹膜转移的诊断及防治. 中国肿瘤临床, 2008, 35(15): 895-899.
19.	Kagawa S, Shigeyasu K, Ishida M, et al. Molecular diagnosis and therapy for occult peritoneal metastasis in gastric cancer patients. World J Gastroenterol, 2014, 20(47): 17796-17803.
20.	李鹏, 左联华, 田华, 等. 进展期胃癌术前腹腔镜探查的临床意义. 腹腔镜外科杂志, 2009, 14(9): 663-665.
21.	余国庆, 赫永金, 许勇, 等. 腹腔镜在胃癌 T 分期和腹膜转移判断中的应用. 肿瘤学杂志, 2013, 19(4): 312-313.
22.	王舒宝. 胃癌手术方法的改进及无瘤操作技术. 中国实用外科杂志, 2001, 21(7): 407-408.
23.	李胜云, 白冰, 徐振亚. 腹腔灌注冲洗疗法对游离胃癌细胞腹腔转移的预防作用. 郑州大学学报(医学版), 2013, 48(2): 266-269.
24.	Ji ZH, Peng KW, Yu Y, et al. Current status and future prospects of clinical trials on CRS+HIPEC for gastric cancer peritoneal metastases. Int J Hyperthermia, 2017, 26: 1-33.
25.	Liu L, Zhang N, Min J, et al. Retrospective analysis on the safety of 5 759 times of bedside hyperthermic intra-peritoneal or intra-pleural chemotherapy (HIPEC). Oncotarget, 2016, 7(16): 21570-21578.
26.	Yonemura Y, Canbay E, Li Y, et al. A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. Eur J Surg Oncol, 2016, 42(8): 1123-1131.
27.	Sato Y, Ohnuma H, Nobuoka T, et al. Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study. Gastric Cancer, 2017, 20(3): 517-526.
28.	朱正纲. 胃癌腹膜转移综合治疗的若干进展. 中华实验外科杂志, 2015, 32(9): 2039-2041.
29.	朱正纲. 胃癌腹膜转移转化性治疗的临床意义. 中国肿瘤外科杂志, 2016, 8(4): 213-216.
30.	Fujiwara Y, Takiguchi S, Nakajima K, et al. Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination. Ann Surg Oncol, 2011, 18(13): 3726-3731.
31.	Imano M, Okuno K. Treatment strategies for gastric cancer patients with peritoneal metastasis. Surg Today, 2014, 44(3): 399-404.
32.	Peng YF, Imano M, Itoh T, et al. A phase Ⅱ trial of perioperative chemotherapy involving a single intraperitoneal administration of paclitaxel followed by sequential S-1 plus intravenous paclitaxel for serosa-positive gastric cancer. J Surg Oncol, 2015, 111(8): 1041-1046.
33.	Koizumi W, Kim YH, Fujii M, et al. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol, 2014, 140(2): 319-328.
34.	Nishikawa K, Yamada Y, Ishido K, et al. Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase Ⅲ study of S-1 plus oxaliplatin versus S-1 plus cisplatin. Gastric Cancer, 2017, 20(4): 640-645.
35.	Kinoshita J, Fushida S, Tsukada T, et al. Efficacy of conversion gastrectomy following docetaxel, cisplatin, and S-1 therapy in potentially resectable stage Ⅳ gastric cancer. Eur J Surg Oncol, 2015, 41(10): 1354-1360.
36.	Kitayama J, Ishigami H, Yamaguchi H, et al. Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites. Ann Surg Oncol, 2014, 21(2): 539-546.
37.	Kodera Y. Gastric cancer with minimal peritoneal metastasis: is this a sign to give up or to treat more aggressively? Nagoya J Med Sci, 2013, 75(1-2): 3-10.
38.	刘书尚, 刘克, 刘震, 等. 减瘤手术对胃癌腹腔内种植转移患者生存时间的影响 . 中华胃肠外科杂志, 2016, 19(1): 37-40.
39.	Boerner T, Graichen A, Jeiter T, et al. CRS-HIPEC prolongs survival but is not curative for patients with peritoneal carcinomatosis of gastric cancer. Ann Surg Oncol, 2016, 23(12): 3972-3977.
40.	Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376(9742): 687-697.

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin, 2017, 67(1): 7-30.
2. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
3. Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends-An update. Cancer Epidemiol Biomarkers Prev, 2016, 25(1): 16-27.
4. 梁寒. 腹腔热灌注化疗技术临床应用专家共识(2016 版)解读—胃癌腹膜转移的防治.临床外科杂志, 2017, 25(1): 20-23.
5. 宾业鸿, 胡晓桦. 胃癌腹膜转移发病机制及治疗的研究进展. 广西医学, 2016, 38(10): 1422-1426.
6. Yamamoto M, Baba H, Kakeji Y, et al. Prognostic significance of tumor markers in peritoneal lavage in advanced gastric cancer. Oncology, 2004, 67(1): 19-26.
7. 朱正纲. 充分重视胃癌腹膜转移的预防、诊断与治疗. 外科理论与实践, 2003, 8(1): 16-17.
8. 戴冬秋. 胃癌腹膜转移研究之策略. 世界华人消化杂志, 2005, 13(9): 1049-1051.
9. 何涛, 杨志明, 伍晓汀. 胃癌腹膜播散转移机理的研究进展. 中国普外基础与临床杂志, 2005, 12(1): 43-45.
10. 赵宏伟, 刘宏斌, 李文惠. 胃癌腹膜转移机理研究现状. 现代肿瘤医学, 2009, 17(5): 978-981.
11. Sodek KL, Murphy KJ, Brown TJ, et al. Cell-cell and cell-matrix dynamics in intraperitoneal cancer metastasis. Cancer Metastasis Rev, 2012, 31(1-2): 397-414.
12. 王松岩, 任克, 刘伟. 胃癌腹膜转移的 CT 诊断价值与影像分析(附45例分析). 中国临床医学影像杂志, 2002, 13(4): 296-297.
13. 刘移忠. 胃癌腹膜转移的螺旋 CT 诊断. 中国当代医药, 2011, 18(17): 63, 66.
14. 严超, 朱正纲, 燕敏, 等. 多排 CT 对胃癌腹膜转移术前预测的单中心大宗病例研究. 中华胃肠外科杂志, 2010, 13(2): 106-110.
15. 杨秋蒙, 坂东悦郎, 川村泰一, 等. PET-CT 诊断胃癌腹膜转移的临床价值. 上海交通大学学报(医学版), 2007, 27(5): 573-576.
16. 周江枫, 岳建国, 贺锋, 等. MSCT 及 PET-CT 对胃癌腹膜转移的诊断价值探讨. 山东医药, 2013, 53(6): 59-60.
17. De Andrade JP, Mezhir JJ. The critical role of peritoneal cytology in the staging of gastric cancer: an evidence-based review. J Surg Oncol, 2014, 110(3): 291-297.
18. 张贤坤, 朱万坤, 韩晓鹏, 等. 胃癌腹膜转移的诊断及防治. 中国肿瘤临床, 2008, 35(15): 895-899.
19. Kagawa S, Shigeyasu K, Ishida M, et al. Molecular diagnosis and therapy for occult peritoneal metastasis in gastric cancer patients. World J Gastroenterol, 2014, 20(47): 17796-17803.
20. 李鹏, 左联华, 田华, 等. 进展期胃癌术前腹腔镜探查的临床意义. 腹腔镜外科杂志, 2009, 14(9): 663-665.
21. 余国庆, 赫永金, 许勇, 等. 腹腔镜在胃癌 T 分期和腹膜转移判断中的应用. 肿瘤学杂志, 2013, 19(4): 312-313.
22. 王舒宝. 胃癌手术方法的改进及无瘤操作技术. 中国实用外科杂志, 2001, 21(7): 407-408.
23. 李胜云, 白冰, 徐振亚. 腹腔灌注冲洗疗法对游离胃癌细胞腹腔转移的预防作用. 郑州大学学报(医学版), 2013, 48(2): 266-269.
24. Ji ZH, Peng KW, Yu Y, et al. Current status and future prospects of clinical trials on CRS+HIPEC for gastric cancer peritoneal metastases. Int J Hyperthermia, 2017, 26: 1-33.
25. Liu L, Zhang N, Min J, et al. Retrospective analysis on the safety of 5 759 times of bedside hyperthermic intra-peritoneal or intra-pleural chemotherapy (HIPEC). Oncotarget, 2016, 7(16): 21570-21578.
26. Yonemura Y, Canbay E, Li Y, et al. A comprehensive treatment for peritoneal metastases from gastric cancer with curative intent. Eur J Surg Oncol, 2016, 42(8): 1123-1131.
27. Sato Y, Ohnuma H, Nobuoka T, et al. Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study. Gastric Cancer, 2017, 20(3): 517-526.
28. 朱正纲. 胃癌腹膜转移综合治疗的若干进展. 中华实验外科杂志, 2015, 32(9): 2039-2041.
29. 朱正纲. 胃癌腹膜转移转化性治疗的临床意义. 中国肿瘤外科杂志, 2016, 8(4): 213-216.
30. Fujiwara Y, Takiguchi S, Nakajima K, et al. Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination. Ann Surg Oncol, 2011, 18(13): 3726-3731.
31. Imano M, Okuno K. Treatment strategies for gastric cancer patients with peritoneal metastasis. Surg Today, 2014, 44(3): 399-404.
32. Peng YF, Imano M, Itoh T, et al. A phase Ⅱ trial of perioperative chemotherapy involving a single intraperitoneal administration of paclitaxel followed by sequential S-1 plus intravenous paclitaxel for serosa-positive gastric cancer. J Surg Oncol, 2015, 111(8): 1041-1046.
33. Koizumi W, Kim YH, Fujii M, et al. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol, 2014, 140(2): 319-328.
34. Nishikawa K, Yamada Y, Ishido K, et al. Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase Ⅲ study of S-1 plus oxaliplatin versus S-1 plus cisplatin. Gastric Cancer, 2017, 20(4): 640-645.
35. Kinoshita J, Fushida S, Tsukada T, et al. Efficacy of conversion gastrectomy following docetaxel, cisplatin, and S-1 therapy in potentially resectable stage Ⅳ gastric cancer. Eur J Surg Oncol, 2015, 41(10): 1354-1360.
36. Kitayama J, Ishigami H, Yamaguchi H, et al. Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites. Ann Surg Oncol, 2014, 21(2): 539-546.
37. Kodera Y. Gastric cancer with minimal peritoneal metastasis: is this a sign to give up or to treat more aggressively? Nagoya J Med Sci, 2013, 75(1-2): 3-10.
38. 刘书尚, 刘克, 刘震, 等. 减瘤手术对胃癌腹腔内种植转移患者生存时间的影响 . 中华胃肠外科杂志, 2016, 19(1): 37-40.
39. Boerner T, Graichen A, Jeiter T, et al. CRS-HIPEC prolongs survival but is not curative for patients with peritoneal carcinomatosis of gastric cancer. Ann Surg Oncol, 2016, 23(12): 3972-3977.
40. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 2010, 376(9742): 687-697.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research progress of peritoneal metastasis from gastric cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content